Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2023 Earnings Call Transcript

Again, we’ll need to see how that timeline comes out in our interactions with the FDA. But apart from CapEx, I think the guidance that we’ve already given would suggest that the cash flows should be moving in the right direction next year. But I just — I feel more comfortable giving qualitative guidance at this point, as opposed to quantitative. But it’s all moving in the right direction.

Q – Mike Petusky: Great. And then just one more. Obviously, you’re getting some questions on Integrity and how quickly that can ramp and I’m sure everybody is sort of curious about what was the actual — the actual contribution of RevoMotion, X-Twist, et cetera in the quarter. Have you guys given any thought as you look at 2024, and how you guys are going to sort of report all that out and communicate to in some way trying to quantify or give greater detail on some of these new products since it seems to me, are so critical in terms of just the overall thesis here?

Cheryl Blanchard: Yes, I appreciate the question. I mean, our business is still small enough, that — we’re obviously, reporting the way we are just to make sure that we provide valuable information that will trend. As we continue to grow, and as we see a lot of these products making contributions that we think are worthwhile reporting out, then we’ll definitely consider that going forward Mike.

Q – Mike Petusky: All right. Very good. Thanks, guys.

Cheryl Blanchard: You’re welcome. Thank you.

Operator: Ladies and gentlemen this concludes today’s question-and-answer session and today’s conference call. We thank you all for attending today’s presentation. You may now disconnect your lines and have a wonderful evening.